Claros' UV System Destroys TFA in Bachem's Swiss GLP-1 Wastewater
Minneapolis – September 22, 2026 -- Claros Technologies has completed a two-week commercial-scale pilot of its ClarosTechUVTM system at Bachem AG's flagship manufacturing campus in Bubendorf, Switzerland, meeting or exceeding the pharmaceutical company's performance metrics for destroying trifluoroacetic acid (TFA) in industrial wastewater.
The trial marks Claros' entry into pharmaceutical manufacturing and expands its commercial footprint in Europe. Bachem, a listed producer of peptide and oligonucleotide APIs including semaglutide, the active ingredient in GLP-1 therapies for weight management and type 2 diabetes, ran the pilot under real-world production conditions.